HIV Drug Market to Reach $26,458 Million, Globally by 2022

Portland, OR -- (SBWire) -- 02/27/2018 --North America and Europe are expected to dominate the global HIV drug market during the forecast period, while emerging countries in Asia-Pacific and Latin America are expected to offer significant growth opportunities.

Global HIV Drug Market was valued at $20,448 million in 2015 and is expected to garner $26,458 million by 2022, registering a CAGR of 3.7% during the forecast period 2016-2022. Human immunodeficiency virus (HIV) is one of the most infectious diseases with around 36.7 million people suffering by the end of 2015, according to The Joint United Nations Programme on HIV/AIDS (UNAIDS).

Get PDF Brochure For Details: https://www.alliedmarketresearch.com/request-sample/1867

The major factors that boost the HIV drug market growth include increase in prevalence of HIV and rise in treatment & diagnosis rate. Moreover, there is an increase in the government initiative to increase awareness among people about HIV cause, symptoms, available treatment options, and the crucial role of these treatments in the control of HIV virus growth. Thus, rise in awareness through such government initiatives are also expected to drive the HIV drugs market. However, stringent government regulations for the approval and commercialization of HIV drugs is expected to restrain the industry growth.

Multi-class combination drugs segment had accounted for more than one-third revenue of the overall HIV drug market in 2015, owing to increase in adoption of combination drugs from this medication class due to their better results in the control of HIV & related coinfections and their ease in consumption & adherence. Increase in the number of HIV infected patients across the globe increases the need for effective treatment for HIV related diseases. Use of Multi-class combination products is an efficient way of treating HIV. Atripla and Prezista are among the blockbuster combination drugs used in the HIV treatment.

Connect to analyst: https://www.alliedmarketresearch.com/connect-to-analyst/1867

According to WHO, 36.7 million people were diagnosed with HIV/AIDS in 2015, whereas, 1.1 million people died of AIDS-related illness in the same year. The world has very high prevalence of people living with HIV owing to the various factors, such as lack of availability of medication for the treatment of HIV infection. In the emerging nations including sub-Saharan Africa, countries with low income do not have sufficient funds to buy high price drugs leading to increase in the population living with HIV.

Key findings of HIV Drug Market

In 2015, multi-class combination drugs segment was the leading medication class segment.

The branded drug Triumeq of multi-class combination drug segment is estimated to grow at the CAGR of 20.7%.

North America market is projected to grow at a CAGR of 3.4% during analysis period.

The Nucleoside Reverse Transcriptase Inhibitors (NRTIs) segment is estimated to grow at the CAGR of 0.4%.

The major companies profiled in the report include Boehringer Ingelheim International GmbH, Merck & Co., Inc., ViiV Healthcare, AbbVie, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb, Gilead Sciences, Inc., Johnson & Johnson, and Cipla Limited.

Enquiry About Report: https://www.alliedmarketresearch.com/purchase-enquiry/1867